Our Grants

CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.

See our complete portfolio of awards below.

View Funded Institutions
View Funded Investigators
Find Clinical Trials

All CIRM Grants

Search Filters »

Institution Researcher name Grant Type Grant Title Award Value
University of California, Los Angeles Dr. Kathrin Plath Dr. Basic Biology IV Understanding the status of the X chromosomes in human ESCs and preimplantation embryos $1,382,400
Gladstone Institutes, J. David Dr. Steve M. Finkbeiner Basic Biology IV Common molecular mechanisms in neurodegenerative diseases using patient based iPSC neurons $1,395,184
Stanford University Alexander Robert Dunn Basic Biology IV Role of mechanical signaling in stem cell self-renewal and differentiation $1,062,998
Stanford University Dr. Anne Brunet Basic Biology IV Energy metabolism and aging pathways in human stem cell reprogramming and differentiation $1,414,044
University of California, San Francisco Dr. Miguel Ramalho-Santos Basic Biology IV Genetic dissection of human cellular reprogramming to pluripotency $1,184,883
Gladstone Institutes, J. David Sheng Ding PhD Basic Biology IV A new paradigm of lineage-specific reprogramming $1,568,395
Stanford University Michael Cleary Basic Biology IV Prostaglandin pathway regulation of self-renwal in hematopoietic and leukemia stem cells $1,244,455
Stanford University Michelle Monje Basic Biology IV Stem Cell Mechanisms Governing Discrete Waves of Gliogenesis in the Childhood Brain $1,264,248
University of California, San Diego Dr. Gene Wei-Ming Yeo Basic Biology IV Stem cell models to analyze the role of mutated C9ORF72 in neurodegeneration $1,260,360
Cedars-Sinai Medical Center Professor Clive Niels Svendsen iPSC Consortia Award The HD iPSC Consortium: Repeat Length Dependent Phenotypes for Assay Development $300,000
Stanford University Dr. Joseph C. Wu Disease Team Therapy Development – Research Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure $19,060,330
Capricor, Inc Dr. Rachel Ruckdeschel Smith Disease Team Therapy Development – Research Allogeneic Cardiac-Derived Stem Cells for Patients Following a Myocardial Infarction $14,405,857
University of California, Los Angeles Dr. Antoni Ribas MD/PhD Disease Team Therapy Development – Research Genetic Re-programming of Stem Cells to Fight Cancer $14,144,221
University of California, Los Angeles Dr. Stanley Nelson Disease Team Therapy Development – Research Combination Therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy $0
University of California, Irvine Dr. Henry John Klassen Disease Team Therapy Development – Research Retinal progenitor cells for treatment of retinitis pigmentosa $17,144,825
Cedars-Sinai Medical Center Professor Clive Niels Svendsen Disease Team Therapy Development – Research Progenitor Cells Secreting GDNF for the Treatment of ALS $16,168,464
StemCells, Inc. Dr. Alexandra Capela Disease Team Therapy Development – Research Restoration of memory in Alzheimer’s disease: a new paradigm using neural stem cell therapy $8,901,641
Stanford University Dr. Judith A Shizuru Disease Team Therapy Development – Research A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants $18,990,683
University of California, Davis Dr. John Laird Disease Team Therapy Development – Research Phase I study of IM Injection of VEGF-Producing MSC for the Treatment of Critical Limb Ischemia $3,728,384
University of California, Davis Dr. Vicki Wheelock Disease Team Therapy Development – Research MSC engineered to produce BDNF for the treatment of Huntington’s disease $8,924,235
StemCells, Inc. Dr. Nobuko Uchida Disease Team Therapy Development – Research Neural stem cell transplantation for chronic cervical spinal cord injury $0
University of California, Davis Nancy E. Lane Disease Team Therapy Development – Research Treatment of non-traumatic osteonecrosis with endogenous Mesenchymal stem cells $18,227,898
Salk Institute for Biological Studies Dr. David R Schubert Early Translational III Stem cell based small molecule therapy for Alzheimer’s disease $1,673,757
City of Hope, Beckman Research Institute Dr. Stephen J Forman Early Translational III Targeting glioma cancer stem cells with receptor-engineered self-renewing memory T cells $5,215,447
Gladstone Institutes, J. David Dr. Deepak Srivastava Early Translational III Direct Cardiac Reprogramming for Heart Regeneration $5,795,871
University of California, San Diego Dr. Lawrence S. B. Goldstein Early Translational III Identifying Drugs for Alzheimer’s Disease with Human Neurons Made From Human IPS cells $1,774,420
University of California, San Diego Dr Yang Xu Early Translational III Human ES cell based therapy of heart failure without allogenic immune rejection $1,857,600
Stanford University Dr. Joseph C. Wu Early Translational III Heart Repair with Human Tissue Engineered Myocardium $4,395,080
University of California, San Francisco Dr Morton Cowan Early Translational III Gene Correction of Autologous Hematopoietic Stem Cells in Artemis Deficient SCID $3,862,367
Stanford University Professor Helen M. Blau PhD Early Translational III Local Delivery of Rejuvenated Old Muscle Stem Cells to Increase Strength in Aged Patients $1,825,283
University of Southern California Dr. Toshio Miki Early Translational III Generation of hepatic cell from placental stem cell for congenital metabolic disorders $1,750,375
Children’s Hospital of Orange County Philip Schwartz Ph.D. Early Translational III Immune-Matched Neural Stem Cell Transplantation for Pediatric Neurodegenerative Disease $4,266,015
University of California, San Francisco Dr. Holger F Willenbring Early Translational III Generation of safe and therapeutically effective human induced hepatocyte-like cells $1,544,170
Salk Institute for Biological Studies Juan Carlos Izpisua Belmonte Early Translational III Direct reprogramming towards vascular progenitors for the treatment of ischemia $2,340,000
University of California, San Diego Dr. Eric D. Adler Early Translational III Identification of Novel Therapeutics for Danon Disease Using an iPS Model of the Disease $1,701,575
University of California, Davis Walter Douglas Boyd Early Translational III Extracellular Matrix Bioscaffold Augmented with Human Stem Cells for Cardiovascular Repair $4,631,754
Stanford University Dr. Bertha Chen Early Translational III Autologous iPSC Therapy for Urinary Incontinence $4,715,738
University of California, San Diego Mark H Tuszynski Early Translational III Functional Neural Relay Formation by Human Neural Stem Cell Grafting in Spinal Cord Injury $4,600,447
University of California, Davis Prof. Kyriacos A. Athanasiou Ph.D Early Translational III Tissue engineered cartilage from autologous, dermis-isolated, adult, stem (DIAS) cells $1,735,703
University of California, Irvine Craig Michael Walsh Early Translational III Multiple Sclerosis therapy: Human Pluripotent Stem Cell-Derived Neural Progenitor Cells $4,535,005
Stanford University Dr. Katja Weinacht Preclinical Stage Projects Therapeutic Restoration of Immune Function through iPSC-derived Human Thymic Epithelial Cells $12,999,871
EVADE Therapeutics Sonja Schrepfer Preclinical Stage Projects Hypoimmune Stem Cell–Derived Islets: A Next-Generation Cell Therapy Toward a Functional Cure for Type 1 Diabetes $12,480,000
University of Southern California Charles Murry Preclinical Stage Projects Regenerating the Acutely Infarcted Heart with iPSC-Ventricular Cardiomyocytes. $6,891,118
University of California, Los Angeles Dr. Lili Yang Preclinical Stage Projects Stem Cell-Engineered Off-The-Shelf CAR-NKT Cell Therapy for Multiple Sclerosis $7,499,996
Scribe Therapeutics Brett Staahl Preclinical Stage Projects A First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent Cardiovascular Events $12,714,480
4D Molecular Therapeutics, Inc. Sara Collins Preclinical Stage Projects Gene Therapy for Alpha-1 Anti-Trypsin Deficiency $5,915,073
AcuraStem Incorporated Mr. Samuel V. Alworth MS, MBA Preclinical Stage Projects Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies $7,500,000
Cure Rare Disease Dr. Tahseen Mozaffar Preclinical Stage Projects Advancement of a myotropic, liver-detargeting therapy for LGMD2i/R9 $7,292,297
Scribe Therapeutics Brett Staahl Preclinical Stage Projects A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia $13,000,000
Savanna Biotherapeutics, Inc. Dr. Sunil Gandhi Ph.D Preclinical Stage Projects Microglia replacement therapy for CSF1R-related Leukoencephalopathy $12,993,456
1 … 19 20 21 22 23 24 25 26 27 28 29 30 31 32